FAAH Pharmaceutique Inc
1255 University, # 1610
Montreal Quebec H3B 3X3
FAAH Pharma Inc. based in Montreal,, Quebec, is a project-focused company developing a clinical asset initially for postherpetic neuralgia. The compound is an inhibitor of fatty acid amide hydrolase or “FAAH.” The asset has been tested in the clinic in healthy volunteers and will be studied in a Phase 2a trial.
The company is fully funded to this stage by TVM Life Science Ventures VII and is supported by Dr. Gosse Bruinsma, MD, with over 20 years of leadership experience in biopharmaceutical companies and Mark Cipriano, CPA, with 16 years of venture investment experience following a ten year professional accounting career.